This application requests funds to support a mentored Research Career Development Award ("K" series, CDA) for a candidate at Vanderbilt University. The candidate has formal training in chemistry and imaging sciences, and seeks to become an independent investigator within the field of molecular imaging. Funds to support this application will facilitate critical training in cancer biology, high-throughput screening, and mass spectrometry. A career development plan has been established that includes didactic training, laboratory training, and a research plan that ensures future success as an independent investigator. The proposed research seeks to develop quantitative, high-throughput screening (HTS) technology to accelerate the discovery and development of small molecule molecular imaging agents (MIAs). Ml is an emerging research tool and clinical discipline that aims to non-invasively characterize in vivo molecular processes at the cellular and sub-cellular levels. Currently, the MIA development paradigm is costly, time consuming, and narrow in scope. Given that genomic and proteomic technologies are now being used to rapidly discover novel molecular targets, there is a pressing need to develop new approaches which will accelerate the MIA discovery process. Here, we propose a library-based, HT approach that will enable the discovery of lead compounds with specificity for unique cellular phenotypes. Our approach will be universally applicable to numerous cell-based systems and facilitate quantification of compound uptake without the use of markers or labels. We will validate our methodology by screening for compounds able to selectively label various cell types found within the chronic inflammatory microenvironment of tumors. Under these proposed investigations, cellular-specific small molecules will be discovered in vitro and validated in vivo, with optimal candidates selected for future development as imaging agents. We will meet these goals by synergizing a small molecule HT screen with MALDI-QqTOF-MS according to the following specific aims:
AIM 1 - Develop a quantitative, HT method for screening cellular uptake of library-based small molecules.
AIM 2 - Identify small molecules from the HTS that will discriminate type-1, pro-inflammatory macrophages from type-2, anti-inflammatory macrophages and tumor cells.
AIM 3 - Validate the cellular specificity of lead compounds in vivo. Relevance to public health: In vivo molecular imaging agents are capable of measuring discrete, biological events associated with diseases such as cancer. The goal of this proposed CDA and research is to realize improved molecular imaging agents for translational research.
|Cheung, Yiu-Yin; Nickels, Michael L; Tang, Dewei et al. (2014) Facile synthesis of SSR180575 and discovery of 7-chloro-N,N,5-trimethyl-4-oxo-3(6-[(18)F]fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide, a potent pyridazinoindole ligand for PET imaging of TSPO in cancer. Bioorg Med Chem Lett 24:4466-71|
|Hight, Matthew R; Cheung, Yiu-Yin; Nickels, Michael L et al. (2014) A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells. Clin Cancer Res 20:2126-35|
|McKinley, Eliot T; Zhao, Ping; Coffey, Robert J et al. (2014) 3'-Deoxy-3'-[18F]-Fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer. PLoS One 9:e108193|
|Uddin, Md Imam; Buck, Jason R; Schulte, Michael L et al. (2014) Microwave-assisted, one-pot reaction of 7-azaindoles and aldehydes: a facile route to novel di-7-azaindolylmethanes. Tetrahedron Lett 55:|
|McKinley, Eliot T; Smith, R Adam; Zhao, Ping et al. (2013) 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer. J Nucl Med 54:424-30|
|Tang, Dewei; McKinley, Eliot T; Hight, Matthew R et al. (2013) Synthesis and structure-activity relationships of 5,6,7-substituted pyrazolopyrimidines: discovery of a novel TSPO PET ligand for cancer imaging. J Med Chem 56:3429-33|
|McKinley, Eliot T; Ayers, Gregory D; Smith, R Adam et al. (2013) Limits of [18F]-FLT PET as a biomarker of proliferation in oncology. PLoS One 8:e58938|
|Tang, Dewei; Hight, Matthew R; McKinley, Eliot T et al. (2012) Quantitative preclinical imaging of TSPO expression in glioma using N,N-diethyl-2-(2-(4-(2-18F-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide. J Nucl Med 53:287-94|
|McKinley, Eliot T; Bugaj, Joseph E; Zhao, Ping et al. (2011) 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin Cancer Res 17:3332-40|
|Hight, Matthew R; Nolting, Donald D; McKinley, Eliot T et al. (2011) Multispectral fluorescence imaging to assess pH in biological specimens. J Biomed Opt 16:016007|
Showing the most recent 10 out of 27 publications